Equities Analysts Offer Predictions for CNTB Q3 Earnings

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Connect Biopharma in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.30) per share for the quarter, down from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.50) EPS and FY2030 earnings at ($0.10) EPS.

Connect Biopharma (NASDAQ:CNTB) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. The business had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $0.74 million.

A number of other research analysts have also recently weighed in on CNTB. Oppenheimer initiated coverage on shares of Connect Biopharma in a research note on Thursday, July 9th. They set an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings lowered Connect Biopharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Cantor Fitzgerald assumed coverage on Connect Biopharma in a report on Thursday, May 21st. They set an “overweight” rating and a $4.00 target price on the stock. Piper Sandler assumed coverage on Connect Biopharma in a research report on Friday, June 26th. They set an “overweight” rating and a $7.00 price target for the company. Finally, Canaccord Genuity Group set a $7.00 price target on Connect Biopharma in a report on Friday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.43.

Connect Biopharma Stock Down 2.4%

Shares of NASDAQ CNTB opened at $2.43 on Monday. Connect Biopharma has a 12-month low of $1.23 and a 12-month high of $3.82. The company has a market capitalization of $152.99 million, a PE ratio of -2.04 and a beta of -0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. The firm’s 50-day moving average is $2.23 and its two-hundred day moving average is $2.48.

Institutional Trading of Connect Biopharma

A number of hedge funds have recently bought and sold shares of the company. HRT Financial LP boosted its holdings in shares of Connect Biopharma by 60.5% during the fourth quarter. HRT Financial LP now owns 16,785 shares of the company’s stock worth $47,000 after purchasing an additional 6,328 shares during the last quarter. SmartHarvest Portfolios LLC purchased a new stake in shares of Connect Biopharma in the fourth quarter valued at $36,000. Bank of America Corp DE acquired a new position in Connect Biopharma in the first quarter valued at $41,000. Persistent Asset Partners Ltd acquired a new position in Connect Biopharma in the fourth quarter valued at $76,000. Finally, XTX Topco Ltd purchased a new position in Connect Biopharma during the second quarter worth about $29,000. Institutional investors and hedge funds own 58.72% of the company’s stock.

Insider Activity at Connect Biopharma

In other news, Director James Huang acquired 150,000 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was acquired at an average price of $2.48 per share, with a total value of $372,000.00. Following the completion of the transaction, the director directly owned 13,310,000 shares in the company, valued at approximately $33,008,800. This represents a 1.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.60% of the stock is currently owned by company insiders.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.